Skip to main content
search

When looking at the nicotine products available in today’s market, no discussion is complete without including pharmaceutical-grade synthetic nicotine. Since its recent emergence, this innovation has set itself apart from traditional tobacco plant-derived nicotine by being lab-grown instead.

But what does that mean for the consumer? And what are the benefits? Find out with us below:

  1. What is it?

Pharmaceutical-grade synthetic nicotine is nicotine produced in a laboratory setting through chemical synthesis. This means there is more control over the product’s quality, composition, purity and potency. 

  1. Why is that important? 

The ability to define the characteristics of pharmaceutical-grade synthetic nicotine is important because it allows for the creation of a purified form of nicotine without the harmful byproducts, impurities, contaminants or unwanted ingredients associated with tobacco combustion.

The benefits of synthetic nicotine

This safer synthetic nicotine can then be used in many harm-reduction products and nicotine delivery systems – including e-cigarettes, nicotine patches, and nicotine gums.

  1. How is the quality controlled? 

Synthetic nicotine can only be labelled “pharmaceutical-grade” once it can prove that it has met the strict criteria and regulatory requirements set by established organisations such as the United States Pharmacopeia (USP) or Good Manufacturing Practices (GMP).

It is only once synthetic nicotine has gained this label that it can be used for medical purposes, harm reduction products, and nicotine replacement therapies.

  1. Is this the future of nicotine? 

While nicotine harm reduction products are already much lower on the risk continuum than tobacco products and, especially, tobacco-based cigarettes, pharmaceutical-grade synthetic nicotine provides an even safer, more controlled and rigorously tested alternative. 

The continued popularity of this alternative can also help combat misconceptions and alleviate irrational fears surrounding nicotine. Therefore, it is important to continually increase the interest, research, and awareness surrounding pharmaceutical-grade synthetic nicotine as an important harm-reduction tool. 

THR IN AFRICA

Related Posts

Harm Reduction AfricaNicotine PouchesTHR in AfricaVapingLetter to the World Health Organization (WHO)
27 October 2021

Letter to the World Health Organization (WHO)

Letter to the World Health Organization (WHO) and delegates of the Ninth Conference of Parties (COP9) regarding the Framework Convention…
Oral NicotineVapingPublic Health implications of vaping in Germany
21 November 2021

Public Health implications of vaping in Germany

Prof Levy’s SAVM model predicts 4.7 million life-years saved, and 300,000 deaths avoided by 2060 In Germany’s population of 84…
Vaping Health Implications USADrug Harm ReductionVapingPublic Health implications of vaping in the United States of America
26 November 2021

Public Health implications of vaping in the United States of America

Public health implications of vaping in USA: Prof Levy’s SAVM model predicts 38.9 million life-years saved, and 1.8 million deaths…
Alcohol Harm Reduction

More about

Alcohol Harm Reduction

Drug Harm Reduction

More about

Drug Harm Reduction